While only 2% of adult GBM express BRAF V600E, the incidence of activating oncogenic BRAFV600E mutation is higher across other central nervous system primary tumors in pediatric and adult patients [14]; thus, dabrafenib combined with trametinib represents a potential treatment option for these subsets of CNS tumor patients. The gene discussed is BRAF; the disease is glioblastoma.